There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive
There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now